Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
ATAI Stock Chart & Stats
$4.03
-$0.11(-6.29%)
At close: 4:00 PM EST
$4.03
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$1.38 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)4.81M
Market Cap
$1.52B
Enterprise Value$676.93M
Total Cash (Recent Filing)$256.04M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta1.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding366,916,900
10 Day Avg. Volume4,706,750
30 Day Avg. Volume4,811,811
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue165.55
Enterprise Value/Gross Profit-100.30
Enterprise Value/Ebitda-5.99
Forecast
1Y Price Target
$14.90Price Target Upside269.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2b data indicate BPL-003 delivered a rapid and sustained antidepressant benefit compared with a low-dose group, supporting confidence in its therapeutic potential.
Commercial ScalabilityShort in-clinic administration with a brief post-dose observation period supports a scalable, SPRAVATO-like treatment model that could attract partners or acquirers.
Regulatory ProgressAlignment with the regulator on pivotal trial design and the granting of Breakthrough Therapy designation reduce development and regulatory risk for the lead program.
Bears Say
Financial PositionA large one-time merger-related accounting charge combined with elevated general and administrative costs materially increased reported net losses and heightens financing risk.
Regulatory And Market UncertaintyStart of a registrational Phase 3 program is contingent on favorable End-of-Phase 2 feedback, and a concentrated target market could limit commercial uptake if launch assumptions are not met.
Safety And Tolerability RisksPatient discontinuations for elevated blood pressure and a case of suicidal ideation underline safety issues that could complicate enrollment and regulatory review.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $1.38 and its highest was $6.75 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $1.52B.
When is Atai Beckley N.V.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 366,916,900 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.90 (269.73% Upside)
$14.90 (269.73% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 941.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
174.14%
12-Months-Change
Fundamentals
Return on Equity
-389.74%
Trailing 12-Months
Asset Growth
35.29%
Trailing 12-Months
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
ATAI Stock 12 Month Forecast
Average Price Target
$14.90
▲(269.73% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
32.45% Insiders
0.06% Mutual Funds
2.04% Other Institutional Investors
59.20% Public Companies and Individual Investors